CSL

brand-profile-thumb

Company Headquarters

1020 First Avenue King of Prussia, PA 19406 US

Driving Directions

Brand Description

CSL Behring, a Business Unit of CSL, is a global biotherapeutics leader driven by its promise to save lives. 

Key Personnel

NAME
JOB TITLE
  • Paul McKenzie
    Chief Executive Officer and Managing Director
  • Greg Boss
    Executive Vice President, Legal & General Counsel
  • Herv
    Senior Vice President and General Manager, CSL Vifor
  • Mark Hill
    Chief Digital Information Officer
  • Ken Lim
    Executive Vice President and Chief Strategy Officer
  • Joy Linton
    Chief Financial Officer
  • Bill Mezzanotte
    Executive Vice President, Head of Research & Development
  • Roanne Parry
    Chief Human Resources Officer
  • Kate Priestman
    Chief Corporate & External Affairs Officer
  • Dave Ross
    Senior Vice President & General Manager, CSL Seqirus
  • Andy Schmeltz
    Executive Vice President, CSL Behring

Yearly results

Sales: 13.3 Billion

Headcount: 24,660
Revenues: $13,310 (+31%)
Net Income: $7,250 (+32%)
R&D: $1,232 (+22%)

Melbourne, Australia-based CSL develops and delivers innovative medicines that help people with serious and life-threatening conditions through three businesses: CSL Behring, a global biotherapeutics leader; CSL Seqirus, a leading influenza vaccine provider; and the recently acquired CSL Vifor, a global partner for pharmaceuticals and innovative therapies in iron deficiency and nephrology.

Revenue for fiscal year 2023 was $13.31 billion, up 31% when compared to the prior comparable period, delivered against a challenging operating environment. In particular, the CSL Behring business rebounded strongly driven by growth in immunoglobulin sales and record plasma collections.

Early 2023 was marked by a major leadership transition as Paul Perreault retired from his role as CEO and managing director after 10 years in the position. Dr. Paul McKenzie was appointed as the new chief executive and managing director in March 2023, bringing more than 30 years of leadership experience in the global biotechnology industry, including his time at CSL as the chief operating officer.

In March 2023, CSL celebrated the opening of a new plasma fractionation facility in Marburg, Germany, a $470 million project that took five years to construct. With optimized process flows, modern technologies and automation, the new fractionation facility quadruples the current capacity.

In June 2023, the first patient received FDA approved gene therapy Hemgenix for hemophilia B in the U.S. In March 2024, the FDA approved Vafseo tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.

Most recently, in June, CSL Seqirus was selected by the Health Emergency Preparedness and Response Authority (HERA), part of the European Commission (EC), to provide 665,000 pre-pandemic vaccine doses for fifteen EU and EEA member states as well as to the “Union Civil Protection Mechanism.”

Sales: 9 Billion

Headcount: 25,000
Revenues: $8,951
Net Income: $2,117
R&D: $857
*CSL does not report annual results until 30 June, so data is estimated.

TOP SELLING DRUGS

Drug Indication 2019 Sales (+/-%)
Privigen thrombocytopaenic purpura $2,837 19%
Hizentra immunoglobulin deficiency $1,252 26%
Kcentra haemorrhagic conditions $690 12%
Human albumin blood substitution, liver cirrhosis $669 -34%
Flucelvax influenza prophylaxis $521 21%
Humate P haemophilia A $469 -4%
Idelvion haemophilia B $451 14%
Fluad influenza prophylaxis $340 13%
Haegarda hereditary angioederma $261 1%
Berinert P hereditary angioederma $241 -1%

Sales: 4.6 Billion

Headcount: 10,500
Bio/Pharma Revenue: $4,550 (10%)
Total Revenues: $4,747 (11%)
Net Income: $1,009 (8%)
R&D Budget: $364 (13%)

Top Selling Drugs

Drug Indication $ (+/- %)
Immunoglobulins $1,524 11%
Plasma-derived coagulants $483 1%
Helixate / Recombinant FVIII $409 0%
Albumin $372 9%

Account for 61% of total biopharma sales, down from 63% in previous year.

NOTE: Fiscal year ends June 30, so these results are based on previous fiscal year, ending June 30, 2011

NOTE: Australian dollar appreciated 4% from year to year, creating  jumps in results in USD

Sales: 4.1 Billion

Sales: 3.9 Billion

Headcount: 10,000
Pharma Revenues: $3,930 (23%/4%*)
Total Revenues: $4,082 (8%/-8%*)
Net Income: $929 (8%/-8%*)
R&D Budget: $280 (20%/2%*)

* Converted at avg. exch. rate / based on reported currency (AUD)

Fiscal year ends June 30, so these results are based on previous fiscal year, ending June 30, 2010

Australian dollar appreciated 17% from year to year, creating extreme jumps in results in USD

Top-Selling Drugs in 2010

Drug

Indication

$

(+/- %)

Immunoglobulins

$1,049

9%

Plasma-derived coagulants

$463 2%

Helixate/Recombinant FVIII

$370 1%

Albumin

$309

n/a

Account for 56% of total biopharma sales, same as previous year..

Previous Profile: Biogen Idec. // Next Profile: Genzyme

Related Content